Pune, India -- (SBWIRE) -- 10/19/2017 -- Market Research Future adds new report of "Global Pharmacogenomics Market Research Report - Forecast to 2027" it contains Company information, geographical data and Table of Content

Competitive Analysis:

RPRD (Right Patient Right Drug) Diagnostics, a privately-held, Wisconsin-based precision medicine company, on February 2017, declared a strategic partnership with Orient Bio Inc., a leading South Korean biotechnology company.

An agreement signed during Governor Scott Walker's trade mission to South Korea calls for establishing a business plan in which RPRD Diagnostics will expand the availability of its advanced pharmacogenomics (PGx) testing services into new markets and Orient Bio will diversify its business into new areas, including precision medicine and clinical PGx.

The key players that are involved in global pharmacogenomics market Myriad Genetics, Inc (U.s), Transgenomic, Inc(U.s), 23andMe (U.S), Pathway Genomics (CA), Genetech (CA), GeneDX (U.S), Teva Pharmaceutical Industries Ltd.(Israel), Illumina, Inc.(U.s), Assurex Health, Inc.(U.s), and others.

Get a Sample Report @ https://www.marketresearchfuture.com/sample_request/1177

Market Segments

The market for pharmacogenomics is segmented into mainly three; by application, by therapeutic application, by end user and its various sub-segments.

- By Application include drug safety, Tailor treatments, drug discovery

- By Therapeutic Application Include cancer, oncology, cardiovascular

- By Methods include haplotype analysis, multivariate techniques, quantitative trait analysis

Market Highlight:

Pharmacogenomics is the study of how genes effect on a person's response to drugs. This comparatively latest theory combines pharmacology (the science of drugs) and genomics (the study of genes and their functions) to advance effective, safe medications and doses that will be tailored to a person's genetic condition.

Some of the factors driving the market are increasing prevalence of several infectious and non-infectious diseases, rising use of drug discovery processes, increasing demand for personalized drugs, and developing awareness about benefits related with pharmacogenomics. Illnesses needs proper effective treatment that should be more reliable and safe at the same time. Pharmacogenomics can help to achieve both. Increasing awareness about its benefits is likely to drive demand globally.

Application of pharmacogenomics would seriously benefit physicians in the treatment of a particular segment of population by studying their responses to specific drugs. Additionally, the knowledge of effectiveness of a drug in a patient would make a drug more reliable, and limit the number of drugs to be withdrawn from the market due to different negative reactions in some patients to whom they were reacted.

Several pharmacogenomics tests have been advanced and some are under development. This represents noticeable deliverables of the numerous genomic studies to correlate genetic variation with variable drug response. Certain drugs such as warfarin, thiopurines, clopidogrel, irinotecan, abacavir, carbamazepine, and phenytoin are used for pharmacogenomics tests. These tests are performed for diseases such as excessive clotting disorder, autoimmune/childhood leukemia, cancer, HIV, epilepsy, and psychiatric and related diseases.

Brief TOC

1. Report Prologue
2. Market Introduction
3. Research Methodology
4. Market Dynamics
5. Market Factor Analysis
6. Global Pharmacogenomics Market, By Application
7. Global Pharmacogenomics Market, By Therapeutic Application
8. Global Pharmacogenomics Market, By Methods
9. Global Pharmacogenomics Market, By Region
10. Company Profile
11. Conclusion
12. Appendix

Browse Report Details @ https://www.marketresearchfuture.com/reports/pharmacogenomics-market

Regional Analysis of Pharmacogenomics

North America dominated the global pharmacogenomics market with the largest market share, accounting for million and is expected to grow over billion by 2027. The European market for Pharmacogenomics is expected to grow at GAGR (2016-2027). Asia-Pacific is expected to grow at CAGR from million in 2016 to million by 2027.

About Market Research Future
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.